EP4447939A1 - A film coated tablet formulation comprising benidipine - Google Patents

A film coated tablet formulation comprising benidipine

Info

Publication number
EP4447939A1
EP4447939A1 EP22908124.5A EP22908124A EP4447939A1 EP 4447939 A1 EP4447939 A1 EP 4447939A1 EP 22908124 A EP22908124 A EP 22908124A EP 4447939 A1 EP4447939 A1 EP 4447939A1
Authority
EP
European Patent Office
Prior art keywords
film coated
coated tablet
benidipine
sodium
tablet according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22908124.5A
Other languages
German (de)
French (fr)
Other versions
EP4447939A4 (en
Inventor
Tolga GULER
Nur PEHLIVAN AKALIN
Fatih Sunel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Priority claimed from PCT/TR2022/051469 external-priority patent/WO2023113745A1/en
Publication of EP4447939A1 publication Critical patent/EP4447939A1/en
Publication of EP4447939A4 publication Critical patent/EP4447939A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Definitions

  • the present invention relates to a film coated tablet comprises benidipine in the form of the free base or in the form of pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient, wherein the tablet has a hardness of between 20 N and 70 N. Furthermore, the formulation is obtained using an effective process.
  • Benidipine has the formula 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine- dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester hydrochloride. It is a synthetic dihydropyridine derivative that has anti-hypertensive and anti-anginal actions. It is a triple L-, T-, and N-type calcium channel blocker. The only calcium antagonist that can inhibit all the three Ca channels mentioned. Furthermore, benidipine has highly affinity with cell membrane, has vascular selectivity and renal protection effect. Therefore, it is an ideal, safe and effective agent for the treatment of hypertension and renal parenchymal hypertension and angina. Benidipine has the following chemical structure of Formula I.
  • Benidipine is a class II drug in the BCS classification, that is, poorly water soluble.
  • its dissolution is the rate-limiting process of absorption, and is often the most important factor affecting its bioavailability. It is very soluble in formic acid, freely soluble in dimethylformamide, soluble in methanol or ethanol, slightly soluble in acetic anhydride.
  • benidipine HCI presents in low amounts in the formulation so, excessive use of excipients and incompatibilities between them can adversely affect compressibility. The problem can cause also flowability and content uniformity.
  • Benidipine was originally disclosed with the application EP63365 B2.
  • a film coated tablet comprising benidipine in the form of the free base or in the form of pharmaceutically acceptable salts having has a hardness of between 20 N and 70 N.
  • the tablet has been developed by using standard techniques which is simple and cost-effective method.
  • the main object of the present invention is to eliminate problems caused by benidipine and bringing additional advantages to the relevant prior art.
  • Another object of the present invention is to provide a film coated tablet having a hardness of between 20 N and 70 N comprising benidipine in the form of the free base or in the form of pharmaceutically acceptable salts which is characterized by the desired compressibility and the desired dissolution rate and short disintegration time.
  • Another object of the present invention is to provide a formulation which is characterized by excellent pharmacotechnical properties, such as flowability and content uniformity.
  • Another object of the present invention is to obtain an effective process for the preparation of a film coated tablet formulation comprising benidipine which has the desired compressibility and the desired dissolution.
  • a film coated tablet comprises benidipine in the form of the free base or in the form of pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient, wherein the tablet has a hardness of between 20 N and 70 N. This hardness provides the desired compressibility thus it is not brittle easily, but also provides a high dissolution rate and short disintegration time.
  • benidipine is in the form of is present as benidipine hydrochloride.
  • the amount of benidipine hydrochloride is between 1.0% and 10.0% by weight in the total formulation. Preferably, it is between 1.0% and 6.0% by weight in the total formulation.
  • a film coated tablet comprises at least one pharmaceutically acceptable excipient which is selected from the group comprising fillers, binders, disintegrants, lubricants/glidants, coating agents or mixtures.
  • Suitable fillers are selected from the group comprising lactose monohydrate, microcrystalline cellulose, lactose, mannitol, spray-dried mannitol, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
  • the filler is lactose monohydrate.
  • the amount of fillers is between 70.0% and 88.0% by weight in the total formulation. Preferably, it is between 74.0% and 85.0% or between 77.0% and 83.0% by weight in the total formulation.
  • Suitable binders are selected from the group comprising polyvinylpyrrolidone, sodium carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, natural gums, sucrose, sodium alginate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, alginate, alginic acid, xanthan gum, hyaluronic acid, polysaccharides, carbomer, poloxamer, polyacrylamide, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
  • the binder is polyvinylpyrrolidone.
  • the amount of binders is between 2.0% and 15.0% by weight in the total formulation. Preferably, it is between 2.5% and 10.0% or between 3.0% and 8.0% by weight in the total formulation.
  • Suitable disintegrants are selected from the group comprising pregelatinized starch, crospovidone, croscarmellose sodium, starch, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, low substituted hydroxypropyl cellulose, sodium alginate, corn starch, sodium starch glycolate, sodium glycine carbonate or mixtures thereof.
  • the disintegrant is pregelatinized starch.
  • the amount of disintegrants is between 3.0% and 15.0% by weight in the total formulation. Preferably, it is between 5.0% and 12.0% or between 6.0% and 10.0% by weight in the total formulation.
  • Suitable lubricants/glidants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, talc, colloidal silicon dioxide, corn, calcium stearate, zinc stearate, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, stearic acid, fumaric acid, glyceryl palmito sulphate or mixtures thereof.
  • the lubricant/glidant is magnesium stearate.
  • the amount of lubricant/glidant is between 0.1% and 3.0% by weight in the total formulation. Preferably, it is between 0.5% and 2.0% by weight in the total formulation.
  • Suitable coating agents are selected from the group comprising polymethacrylates, hydroxypropyl methylcellulose, lactose monohydrate, talc, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), talc, glycerine, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), ponceau, iron oxides, pigments, dyes, titanium dioxide, triacetin, coloring agent or mixtures thereof.
  • the coating agents are hydroxypropyl methylcellulose, talc, titanium dioxide, polyethylene glycol.
  • the coating agents are lactose monohydrate, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol, yellow iron oxide, triacetin, ponceau, FD&C Blue.
  • the amount of coating agents is 1.0% to 5.0% by weight by weight in the total formulation.
  • Benidipine in the form of the free base or in the form of pharmaceutically acceptable salts having the following particle sizes is important for formulation. Especially, it positively affects the dissolution properties.
  • the obtained tablets have the desired dissolution profile.
  • particle size means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. malvern analysis).
  • d (0.9) means, the size at which 90% by volume of the particles are finer.
  • d (0.5) means, the size at which 50% by volume of the particles are finer.
  • benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.5) particle size less than 30 pm, preferably less than 25 pm, preferably less than 20 pm, preferably less than 15 pm, preferably less than 10 pm.
  • benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.5) particle size between 1 pm and 10 pm.
  • benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.9) particle size less than 50 pm, preferably less than 35 pm, preferably less than 25 pm, preferably less than 18 pm.
  • Example 2 Film coating tablet
  • Example 3 Film coating tablet
  • a process for example 2 or 3 a) Mixing benidipine hydrochloride, lactose monohydrate and pregelatinized starch and then sieving, b) Dissolving polyvinylpyrrolidone in water, c) Granulating the mixture at step (a) with the granulation solution at step (b), d) Sieving the wet granule and drying the wet granule at fluid bed dryer, e) Sieving the dry granule, f) Adding magnesium stearate and then mixing, g) Compressing the prepared mixture to form tablets h) Coating these tablets with coating agents.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a film coated tablet comprises benidipine in the form of the free base or in the form of pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient, wherein the tablet has a hardness of between 20 N and 70 N. Furthermore, the formulation is obtained using an effective process.

Description

A FILM COATED TABLET FORMULATION COMPRISING BENIDIPINE
Field of the Invention
The present invention relates to a film coated tablet comprises benidipine in the form of the free base or in the form of pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient, wherein the tablet has a hardness of between 20 N and 70 N. Furthermore, the formulation is obtained using an effective process.
Background of the Invention
Benidipine has the formula 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine- dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester hydrochloride. It is a synthetic dihydropyridine derivative that has anti-hypertensive and anti-anginal actions. It is a triple L-, T-, and N-type calcium channel blocker. The only calcium antagonist that can inhibit all the three Ca channels mentioned. Furthermore, benidipine has highly affinity with cell membrane, has vascular selectivity and renal protection effect. Therefore, it is an ideal, safe and effective agent for the treatment of hypertension and renal parenchymal hypertension and angina. Benidipine has the following chemical structure of Formula I.
Formula I: Benidipine
Benidipine is a class II drug in the BCS classification, that is, poorly water soluble. For poorly soluble drugs, its dissolution is the rate-limiting process of absorption, and is often the most important factor affecting its bioavailability. It is very soluble in formic acid, freely soluble in dimethylformamide, soluble in methanol or ethanol, slightly soluble in acetic anhydride. Furthermore, benidipine HCI presents in low amounts in the formulation so, excessive use of excipients and incompatibilities between them can adversely affect compressibility. The problem can cause also flowability and content uniformity.
Benidipine was originally disclosed with the application EP63365 B2. In this invention, to overcome these problems mentioned above, a film coated tablet comprising benidipine in the form of the free base or in the form of pharmaceutically acceptable salts having has a hardness of between 20 N and 70 N. Also, the tablet has been developed by using standard techniques which is simple and cost-effective method.
Detailed Description of the Invention
The main object of the present invention is to eliminate problems caused by benidipine and bringing additional advantages to the relevant prior art.
Another object of the present invention is to provide a film coated tablet having a hardness of between 20 N and 70 N comprising benidipine in the form of the free base or in the form of pharmaceutically acceptable salts which is characterized by the desired compressibility and the desired dissolution rate and short disintegration time.
Another object of the present invention is to provide a formulation which is characterized by excellent pharmacotechnical properties, such as flowability and content uniformity.
Another object of the present invention is to obtain an effective process for the preparation of a film coated tablet formulation comprising benidipine which has the desired compressibility and the desired dissolution.
Hardness test was done with Erweka Tablet Hardness Tester.
According to one embodiment of the invention, a film coated tablet comprises benidipine in the form of the free base or in the form of pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient, wherein the tablet has a hardness of between 20 N and 70 N. This hardness provides the desired compressibility thus it is not brittle easily, but also provides a high dissolution rate and short disintegration time.
Tablets of lower hardness (<20 N) were observed to dissolve very quickly in the first minutes. It was observed that tablets with higher hardness (>70 N) could not be broken, so there were problems in dissolution. Thereof, It has been found that the specified values create a suitable condition for the tablet comprising benidipine.
According to this embodiment of the present invention, benidipine is in the form of is present as benidipine hydrochloride. According to one embodiment of the present invention, the amount of benidipine hydrochloride is between 1.0% and 10.0% by weight in the total formulation. Preferably, it is between 1.0% and 6.0% by weight in the total formulation.
According to one embodiment of the invention, a film coated tablet comprises at least one pharmaceutically acceptable excipient which is selected from the group comprising fillers, binders, disintegrants, lubricants/glidants, coating agents or mixtures.
Suitable fillers are selected from the group comprising lactose monohydrate, microcrystalline cellulose, lactose, mannitol, spray-dried mannitol, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
According to one embodiment of the present invention, the filler is lactose monohydrate.
According to one embodiment of the present invention, the amount of fillers is between 70.0% and 88.0% by weight in the total formulation. Preferably, it is between 74.0% and 85.0% or between 77.0% and 83.0% by weight in the total formulation.
Suitable binders are selected from the group comprising polyvinylpyrrolidone, sodium carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, natural gums, sucrose, sodium alginate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, alginate, alginic acid, xanthan gum, hyaluronic acid, polysaccharides, carbomer, poloxamer, polyacrylamide, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
According to one embodiment of the present invention, the binder is polyvinylpyrrolidone.
According to one embodiment of the present invention, the amount of binders is between 2.0% and 15.0% by weight in the total formulation. Preferably, it is between 2.5% and 10.0% or between 3.0% and 8.0% by weight in the total formulation.
Suitable disintegrants are selected from the group comprising pregelatinized starch, crospovidone, croscarmellose sodium, starch, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, low substituted hydroxypropyl cellulose, sodium alginate, corn starch, sodium starch glycolate, sodium glycine carbonate or mixtures thereof.
According to one embodiment of the present invention, the disintegrant is pregelatinized starch.
According to one embodiment of the present invention, the amount of disintegrants is between 3.0% and 15.0% by weight in the total formulation. Preferably, it is between 5.0% and 12.0% or between 6.0% and 10.0% by weight in the total formulation.
Suitable lubricants/glidants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, talc, colloidal silicon dioxide, corn, calcium stearate, zinc stearate, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, stearic acid, fumaric acid, glyceryl palmito sulphate or mixtures thereof.
According to one embodiment of the present invention, the lubricant/glidant is magnesium stearate.
According to one embodiment of the present invention, the amount of lubricant/glidant is between 0.1% and 3.0% by weight in the total formulation. Preferably, it is between 0.5% and 2.0% by weight in the total formulation.
Suitable coating agents are selected from the group comprising polymethacrylates, hydroxypropyl methylcellulose, lactose monohydrate, talc, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), talc, glycerine, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), ponceau, iron oxides, pigments, dyes, titanium dioxide, triacetin, coloring agent or mixtures thereof.
According to an embodiment of the present invention, the coating agents are hydroxypropyl methylcellulose, talc, titanium dioxide, polyethylene glycol.
According to an embodiment of the present invention, the coating agents are lactose monohydrate, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol, yellow iron oxide, triacetin, ponceau, FD&C Blue.
According to an embodiment of the present invention, the amount of coating agents is 1.0% to 5.0% by weight by weight in the total formulation. Benidipine in the form of the free base or in the form of pharmaceutically acceptable salts having the following particle sizes is important for formulation. Especially, it positively affects the dissolution properties. The obtained tablets have the desired dissolution profile.
As used here in, ‘particle size’ means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. malvern analysis). The term d (0.9) means, the size at which 90% by volume of the particles are finer. The term d (0.5) means, the size at which 50% by volume of the particles are finer.
According to this embodiment of the present invention, benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.5) particle size less than 30 pm, preferably less than 25 pm, preferably less than 20 pm, preferably less than 15 pm, preferably less than 10 pm.
According to this embodiment of the present invention, benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.5) particle size between 1 pm and 10 pm.
According to this embodiment of the present invention, benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.9) particle size less than 50 pm, preferably less than 35 pm, preferably less than 25 pm, preferably less than 18 pm.
According to this embodiment of the present invention, benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.9) particle size between 3 pm and 18 pm.
According to one embodiment of the present invention, the film coated tablet comprises;
- Benidipine hydrochloride
- Lactose mo no hydrate
- Polyvinylpyrrolidone
According to one embodiment of the present invention, the film coated tablet comprises;
- Benidipine hydrochloride
- Lactose mo no hydrate
- Pregelatinized starch
- Polyvinylpyrrolidone
- Magnesium stearate According to one embodiment of the present invention, the film coated tablet is obtained by using a wet granulation method therefore, a simple and low-cost production method was employed. Wet granulation process efficiently counteracts segregation, so it can achieve good dissolution and disintegration properties. In the process, when a granulation solution is prepared with at least one binder and a solvent (preferably water), it was observed that the desired content uniformity is provided. Especially, the problem caused by the use of small amounts of benidipine has been prevented by the wet granulation comprising suitable excipients and steps.
According to one embodiment of the present invention, a process for the preparation of the film coated tablet comprising benidipine comprises the following steps: a) Mixing benidipine hydrochloride, at least one filler and at least one disintegrant and then sieving, b) Dissolving at least one binder in water, c) Granulating the mixture at step (a) with the granulation solution at step (b), d) Sieving the wet granule and drying the wet granule at fluid bed dryer, e) Sieving the dry granule, f) Adding at least one lubricant/glidant and then mixing, g) Compressing the prepared mixture to form tablets h) Coating these tablets with coating agents.
According to one embodiment of the present invention, a process for the preparation of the film coated tablet comprising benidipine comprises the following steps: a) Mixing benidipine hydrochloride, lactose monohydrate and pregelatinized starch and then sieving, b) Dissolving polyvinylpyrrolidone in water, c) Granulating the mixture at step (a) with the granulation solution at step (b), d) Sieving the wet granule and drying the wet granule at fluid bed dryer, e) Sieving the dry granule, f) Adding magnesium stearate and then mixing, g) Compressing the prepared mixture to form tablets h) Coating these tablets with coating agents. Example 1: Film coating tablet
Example 2: Film coating tablet Example 3: Film coating tablet
A process for example 2 or 3; a) Mixing benidipine hydrochloride, lactose monohydrate and pregelatinized starch and then sieving, b) Dissolving polyvinylpyrrolidone in water, c) Granulating the mixture at step (a) with the granulation solution at step (b), d) Sieving the wet granule and drying the wet granule at fluid bed dryer, e) Sieving the dry granule, f) Adding magnesium stearate and then mixing, g) Compressing the prepared mixture to form tablets h) Coating these tablets with coating agents.

Claims

9 CLAIMS
1. A film coated tablet comprising benidipine in the form of the free base or in the form of pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient, wherein the tablet has a hardness of between 20 N and 70 N.
2. The film coated tablet according to claim 1, wherein benidipine is in the form of is present as benidipine hydrochloride.
3. The film coated tablet according to claim 1, wherein the amount of benidipine hydrochloride is between 1.0% and 10.0% by weight in the total formulation.
4. The film coated tablet according to claim 1, wherein at least one pharmaceutically acceptable excipient which is selected from the group comprising fillers, binders, disintegrants, lubricants/glidants, coating agents or mixtures.
5. The film coated tablet according to claim 4, wherein fillers are selected from the group comprising lactose monohydrate, microcrystalline cellulose, lactose, mannitol, spray- dried mannitol, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
6. The film coated tablet according to claim 5, wherein the filler is lactose monohydrate.
7. The film coated tablet according to claim 5, wherein the amount of fillers is between 70.0% and 88.0% by weight in the total formulation.
8. The film coated tablet according to claim 4, wherein binders are selected from the group comprising polyvinylpyrrolidone, sodium carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, natural gums, sucrose, sodium alginate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, alginate, alginic acid, xanthan gum, hyaluronic acid, polysaccharides, carbomer, poloxamer, polyacrylamide, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
9. The film coated tablet according to claim 4, wherein disintegrants are selected from the group comprising pregelatinized starch, crospovidone, croscarmellose sodium, starch, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, low substituted hydroxypropyl cellulose, sodium alginate, corn starch, sodium starch glycolate, sodium glycine carbonate or mixtures thereof. The film coated tablet according to claim 9, wherein the disintegrant is pregelatinized starch. The film coated tablet according to claim 1, wherein benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.5) particle size less than 30 pm, preferably less than 25 pm, preferably less than 20 pm, preferably less than 15 pm, preferably less than 10 pm. The film coated tablet according to claim 1, wherein benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.9) particle size less than 50 pm, preferably less than 35 pm, preferably less than 25 pm, preferably less than 18 pm. The film coated tablet according to claim 1, wherein the film coated tablet comprising;
- Benidipine hydrochloride
- Lactose mo no hydrate
- Polyvinylpyrrolidone A process for the preparation of the film coated tablet comprising benidipine comprises the following steps: a) Mixing benidipine hydrochloride, at least one filler and at least one disintegrant and then sieving, b) Dissolving at least one binder in water, c) Granulating the mixture at step (a) with the granulation solution at step (b), d) Sieving the wet granule and drying the wet granule at fluid bed dryer, e) Sieving the dry granule, f) Adding at least one lubricant/glidant and then mixing, g) Compressing the prepared mixture to form tablets h) Coating these tablets with coating agents.
EP22908124.5A 2021-12-13 2022-12-10 Film-coated tablet formulation containing benidipine Pending EP4447939A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR202119697 2021-12-13
PCT/TR2022/051469 WO2023113745A1 (en) 2021-12-13 2022-12-10 A film coated tablet formulation comprising benidipine

Publications (2)

Publication Number Publication Date
EP4447939A1 true EP4447939A1 (en) 2024-10-23
EP4447939A4 EP4447939A4 (en) 2025-12-03

Family

ID=92894412

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22908124.5A Pending EP4447939A4 (en) 2021-12-13 2022-12-10 Film-coated tablet formulation containing benidipine

Country Status (1)

Country Link
EP (1) EP4447939A4 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030081472A (en) * 2001-03-06 2003-10-17 교와 핫꼬 고교 가부시끼가이샤 Preparations quickly disintegrating in oral cavity
JP5710301B2 (en) * 2011-02-08 2015-04-30 富士フイルム株式会社 Orally disintegrating tablet and method for producing the same
CN102379875A (en) * 2011-10-28 2012-03-21 山东新宝医药有限公司 Compound preparation containing benidipine hydrochloride and metoprolol tartrate and application thereof
CN112807284A (en) * 2019-11-15 2021-05-18 山东华素制药有限公司 Benidipine hydrochloride tablet and preparation method thereof

Also Published As

Publication number Publication date
EP4447939A4 (en) 2025-12-03

Similar Documents

Publication Publication Date Title
CA2592102C (en) Matrix type sustained-release preparation containing basic drug or salt thereof, and method for manufacturing the same
WO2023113744A2 (en) A tablet formulation comprising micronized benidipine
KR102082775B1 (en) Formulation with enhanced water solubility and bioavailability
JP7648698B2 (en) Pharmaceutical composition containing poorly soluble basic drug
WO2023195955A1 (en) A film coated tablet comprising selexi̇pag and its preparation process
US20060159753A1 (en) Matrix type sustained-release preparation containing basic drug or salt thereof
JP7161176B2 (en) Orally disintegrating tablet and manufacturing method thereof
WO2023113745A1 (en) A film coated tablet formulation comprising benidipine
KR102707060B1 (en) Stability and bioavailability enhanced solid dispersion formulations of Olaparib
WO2023195957A1 (en) A film coated tablet comprising selexi̇pag processed with wet granulation
WO2019142207A1 (en) Pharmaceutical compositions comprising ibrutinib
JP7641098B2 (en) Rivaroxaban-containing tablets
WO2019192195A1 (en) Pharmaceutical composition containing dabigatran etexilate and preparation method thereof
EP4447939A1 (en) A film coated tablet formulation comprising benidipine
WO2014115082A1 (en) Pharmaceutical formulations of imatinib
EP4447964A2 (en) A tablet formulation comprising micronized benidipine
CA3042888A1 (en) Pharmaceutical formulation containing tadalafil
WO2013008253A2 (en) Imatinib formulations
JP7511596B2 (en) Rivaroxaban-containing tablets
WO2025259246A1 (en) A tablet composition comprising benidipine
WO2020055359A2 (en) Oral dosage form of sorafenib tosylate
US20080182908A1 (en) Pharmaceutical compositions comprising memantine
WO2025212071A1 (en) A solid dispersion of enzalutamide
US20240390363A1 (en) Granules containing posaconazole
US20230390254A1 (en) Pharmaceutical compositions of ubrogepant and process for preparation thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240610

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_62574/2024

Effective date: 20241125

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOVEL ILAC SANAYI VE TICARET A.S.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20251105

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/20 20060101AFI20251030BHEP

Ipc: A61P 9/12 20060101ALI20251030BHEP

Ipc: A61K 31/4545 20060101ALI20251030BHEP

Ipc: A61K 9/28 20060101ALN20251030BHEP